On February 10, 2021 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that it has entered into a research collaboration agreement with Papyrus Therapeutics to assess the potential of combining their respective proprietary technology platforms to develop a first-in-class oncolytic virus concept with RTK inhibitor functionality (Press release, Targovax, FEB 10, 2021, View Source [SID1234574815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!